A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Linrodostat (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 12 Jul 2018 Protocol has been amended to change in primary endpoint .
- 12 Jul 2018 Planned End Date changed from 30 Nov 2022 to 31 Jul 2020.
- 12 Jul 2018 Planned primary completion date changed from 13 Aug 2020 to 31 Jul 2020.